

Carotid Doppler in Children with Sickle Cell Anemia

Kiran Gaikwad*, Girish Nanoti**

Abstract

The aim of the study was to perform Carotid Doppler in children aged 2-15 years with Sickle cell anemia. We also studied transcranial velocities in Internal carotid arteries & mean velocities in Common carotid, External carotid and Vertebral arteries. Correlation of increased velocity of blood flow with number of blood transfusions in past, HbF levels and Hydroxyurea therapy was also studied. *Materials and Method:* It was a hospital based cross-sectional study conducted in a Tertiary care hospital in Nagpur from 1st March 2016 to 28 February 2017. *Results:* Total 64 patients were enrolled. 51.6% of patients were in age group of 5-10 years. Transcranial velocity in Internal carotid artery between 170-200cm/s was present in 37.5% of patients and 6.25% of patients had TCV of >200cm/s. There was no correlation of TCV with number of blood transfusions in past and HbF levels. Patients who were on Hydroxyurea therapy had reduced transcranial velocities as compared to those who were not on therapy.

Keywords: Transcranial velocity; Sickle Cell Anemia; Hydroxyurea.

Introduction

Sickle cell anemia is a qualitative haemoglobinopathy that affects many systems in body [1]. The complications of sickle cell anemia are usually age dependent. One of the major complications of sickle cell disease is involvement of central nervous system in form of pyogenic meningitis (H. Influenzae & Pneumococcal), stroke, silent infarcts, posterior reversible leucoencephalopathy etc [3]. Stroke is one of the commonest complication of sickle cell disease after the age of 4 years and this can be prevented by doing periodical Doppler examination of carotid and middle cerebral artery and managing patients accordingly [2]. Hence this study was planned "Carotid doppler in children with sickle cell anemia" at our Institute.

Author's Affiliation: *Assistant Lecturer **Associate Professor, Department of Pediatrics, NKP Salve Institute of Medical Science & Lata Mangeshkar Hospital (NKPSIMS & LMH), Nagpur, Maharashtra 440019, India.

Reprint Request: Kiran Gaikwad, Assistant Lecturer, Dept of Pediatrics, NKP Salve Institute of Medical Science & Lata Mangeshkar Hospital, (NKPSIMS & LMH), Nagpur, Maharashtra 440019, India.

E-mail: ksgaikwad@hotmail.com

Received on 21.07.2017, Accepted on 17.08.2017

Aim & Objectives

The aim of the study was to perform Carotid Doppler in children aged 2-15 years with sickle cell anemia.

1. To evaluate Transcranial velocity (TCV) of the Internal carotid arteries (ICA) in patients with sickle cell anemia.
2. Correlation of increased velocity of blood flow in ICA with stroke.
3. Correlation of increased velocity of blood flow ICA with Hb F levels, number of blood transfusions in past and patient on hydroxyurea therapy.
4. To study mean velocities in other arteries CCA, ECA & VA.

Hypotheses: CNS complications in form of Stroke are more in children of older age and TCV velocities can be evaluated using Carotid approach and raised TVV indicate risk factor for stroke.

Study Design: Hospital based cross-sectional study

Study Setting: Paediatric wards of NKPSIMS & LMH, Nagpur.

Study Duration: 1st March 2016 to February 2017.

Inclusion Criteria: All children diagnosed as sickle cell anemia (SS pattern) by Hb Electrophoresis (HPLC method) in the age group of 2-15 years were included.

Exclusion Criteria

1. Children diagnosed with other hemoglobinopathies like Sickle Thal, HbC, Hb D etc.
2. Patients with h/o head injury, convulsions or h/o perinatal asphyxia were excluded.
3. Children < 2 years and > 15 years of age.

Selection of Cases: Children in age group 2-15 years diagnosed as sickle cell anemia by Hb Electrophoresis (HPLC) SS pattern and who attended the opd or were admitted in Pediatric wards were selected.

Methodology: A detail history and clinical examination was done of the selected patients. Written consent was taken from parents and they were explained the procedure and its importance.

Vessels studied were: Internal carotid artery (ICA), External carotid artery (ECA), Common carotid artery (CCA) and Vertebral artery (VA). The USG machine used was Esaote USG with color Doppler, model MyLab 40, with a high frequency probe.

The ultrasonic approach was Carotid approach for evaluation of carotid arteries and sub-occipital approach for the vertebral artery.

Risk stratification of stroke by TCD was based on

the time-averaged mean of the maximum velocity (TAMM) in the distal internal carotid artery and interpreted as follows [2]:

1. Inadequate image-when no readings could be obtained.
2. Unusual low velocity.
3. Normal velocity-Standard risk-all mean velocities < 170 cm/sec.
4. Borderline velocity-Conditional -at least 1 mean velocity of 170 to 199 cm/sec.
5. High velocity-High risk-Abnormal at least 1 mean velocity of 200 cm/sec or higher [2].

Statistical Analysis: Done by Epi info Software and tests applied were Fischer exact and Chi square test.

Table 1: shows age groupwise and sex wise distribution of children of sickle cell anemia in our study. Most of the patients in our study group were more than 5 years of age. As CNS complications occur in age group of children > 5 years of age hence in our study high risk group were more.

For statistical analysis we have categorised our data in 2 velocities- < 200 cm/s & > 200 cm/s, velocities between 170-200 cm/s is conditional.

Table 1: Age wise distribution of patients

Age Group	Male	Female	Frequency	Percent
2-5	2	4	6	9.4
6-10	18	15	33	51.6
11-15	16	9	25	39.1
Total	36	28	64	100.0
Mean ± S.D.				9.71 ± 3.31

Table 2: Mean velocities in Internal Carotid arteries according to age groups

Age Groups	No. of children (n=64)	Velocity ICA		
		<170cm/s	170-200cm/s	>200cm/s
2-5 years	5	0	5(7.8%)	0
6-10 years	33	25 (61%)	6(9.3%)	2(3.1%)
11-15 years	26	14(21%)	10(38.4%)	2(7.6%)

Table 3.1 & 3.2: Shows the relation of velocity of blood flow in ICA with number of blood transfusions in past

No. Blood Transfusions	Velocity ICA	
	<200	>200
<10	49	1
>10	11	3

Fisher exact P = 0.06

No. Blood Transfusion	Velocity ICA	
	<170	>170
<10	37	16
>10	6	5

Chi square = 0.96, P=0.32

Table 4.1 & 4.2: Shows relation of velocity of blood flow in ICA with Hb F levels

HbF	Velocity ICA	
	<200	>200
<20	37	4
>20	23	0
Fisher exact p= 0.31		

HbF	Velocity ICA	
	<170	>170
<20	22	19
>20	21	2
Chi square= 9.47, p=0.002		

Table 5.1 & 5.2: Shows relation of velocity of blood flow in ICA with patient on Hydroxyurea therapy

Hydroxyurea	Velocity ICA	
	<200	>200
Yes	39	0
No	21	4
Fisher exact p= 0.039		

Hydroxyurea	Velocity ICA	
	<170	>170
Yes	35	4
No	8	17
Chi square= 23.04, p=0.000015		

Discussion

In our case study total 64 patients, 51.6% of patients were in age group between 5-10 years (Table 1). Neish et al, conducted a study in Children's Health Care of Atlanta at Scottish Rite, where they enrolled 66 children of mean age of 9.3 yrs (range 3.8-19 yrs) which was similar to our study [6]. Pawlak et al, 2009 conducted a study in which they enrolled 68 children with mean age of 7.1±3.3 yrs (range, 2- 14 yrs) at a Hospital of University of Pennsylvania, U.S [7]. Study by Munube et al on prevalence of stroke in children admitted with sickle cell anemia, the mean age was 6.1 years [8].

Of the total 64 patients in our study, 4 (6.25%) patients had transcranial velocity in ICA of >200cm/s, 24 (37.5%) patients had velocity of 170-200cm/s (conditional velocity) while 36 (56.2%) patients had velocity below 170cm/s. (Table 2). In study done by Deane et al mean velocity in extracranial velocity was 148cm/s [5]. In another study by Singhal et al, they compared mean velocities in CCA, ECA, ICA, VA in children with sickle cell disease and normal children and found higher mean velocities in sickle cell group [4].

Out of 64 patients, (50%) had received less than 10 times blood transfusion in past and 14% patient

had >10 blood transfusion in their lifetime. On further analysis blood transfusion <10 times whose TCV velocity was >200cm/s was 1(1.5%), while those who needed blood transfusion > 10 times with TCV >200cm/s were 3 (4.6%) (Table 3.1). On applying Fischer exact test P value was 0.06 i.e. >0.05, so statistically not significant. Number of blood transfusions in past is not significant with increase TCV (>200c/s) in our study. Studies like the STOP trial and by Estcourt LJ et al studied relation of blood transfusion in preventing stroke and found normal velocities in children who received regular blood transfusions [2,9].

HbF levels <20 there were 41(64%) patients, while HbF>20 were 23 (35.9%) patients (Table 4.1). In our study group with HbF levels >20 we did not find any patient of HbF levels >20 whose TCV was >200 cm/s while 4(6.2%) patients had HbF levels <20 with TCV>200cm/s. We have applied Fischer exact test for statistical significance and p value was 0.31. Hence amount of Hb F present in a case of SCA does not influence increase in TCV in our study. In studies by Nancy et al & Kratovil et al have suggested the protective role of Hb F from complication [10,11].

Third factor that was correlated was whether the patient was on Hydroxyurea therapy. (Table 5.1) 39 (60.9%) patients out of 64 were on hydroxyurea while

25 (39%) patients were not taking hydroxyurea. Statistically after applying Fischer Exact test between these two group pvalue was 0.034 i.e. less than 0.05 which is statistically significant. As HbF has protective effect against prevention of complications hence hydroxyurea by increasing HbF levels reduces complications, number of hospitalizations and hence the morbidity. [10,11,12,13].

As incidence of stroke increases with TCV >200cm/s but patients with velocity 170-199 cm/s also have high chances of progressive increase in velocity and sooner they will have velocity >200 cm/s. So this velocity of 170-199 cm/sec comes under the category of borderline velocity-conditional, hence we have also done statistical analysis of patients with TCV <170cm/sec and >170cm/sec. In our study of 64 patients, 43 (67.1%) patients had TCV <170cm/s while 21 (32.8%) patients had >170cm/s. We have analysed these data and tried to find statistical correlation between no. of blood transfusions, HbF and patient on Hydroxyurea.

In our study 16 (25%) patients had received >10 times blood transfusion in past whose TCV was >170cm/s while 5 (7.8%) patients received >10 times blood transfusions and TCV in these patients was >170cm/s. By applying Chi square test p value was 0.32 which was not significant. There was no relation of increase in TCV and number of blood transfusions patient had received (Table 3.2).

In our study with TCV <170cm/s, 22 (34.4%) patients had HbF levels <20 while remaining 21 (32.8%) patients had HbF >20 while in another group of TCV >170cm/s HbF level was less than 20 in 19 (29.6%) patients and 2 (3.1%) patients had TCS >170cm/s (Table 4.2). By applying Chi square P value was 0.002 which was less than 0.05 hence it is statistically significant i.e. there is correlation between amount of HbF present and increase in TCD velocity. Hence increase in HbF levels protects against increase in TCV.

39 (60.9%) patients were on Hydroxyurea therapy whereas 23 (35.9%) patients were not on Hydroxyurea. The TCV of patients who were on Hydroxyurea was less than 170 cm/sec in 35 (54.6%) patients while in 41 (64%) it was >170cm/s. (Table 5.2). Study by Ghafari DL et al, they found that hydroxyurea therapy started for disease severity prevention decreases the prevalence of abnormal TCD velocities [14]. The SACRED trial states that hydroxyurea lowers the TCD velocities and prevents conversion from conditional (170-199cm/s) to abnormal (greater than or equal to 200cm/s) velocities [13].

In 25 (39%) patients who were not on Hydroxyurea 8 (12.5%) patients had TCV <170cm/s while 17 (26.5%) patients had TCV >170cm/s. By applying Chi square test p value was 0.00015 which was less than 0.05 and hence statistically significant. Hence Hydroxyurea has a protective value against increase in TCV (Table 5.2). Similar results were there in study by Jane et al in which they inferred that hydroxyurea reduces TCD velocities in children with SCA and conditional velocities [12].

The mean velocities in CCA(R) was 110cm/s, CCA(L) 109cm/s, ECA (R) 102 cm/s, ECA(L) 104cm/s, VA (R) 86cm/s, VA (L) 86.7cm/s. Velocities in extracranial arteries have been studied by Deane & Singhal et al in which they found increased velocities in these vessels in children of sickle cell anemia and hence they can be used as screening vessels. In the carotid vessels the sensitivity in identifying and measuring these vessels is more than intracranial vessels and hence carotid vessels can be used as screening vessels in patients with sickle cell anemia [4,5].

Conclusion

In patients of Sickle cell anemia stroke is one of the major complications. Doppler screening for transcranial velocities can help detect patients at risk of stroke. Number of blood transfusions in past has no relation with stroke.

Raised HbF levels and Hydroxyurea therapy is protective.

Carotid vessels can be used as screening vessels in patients with sickle cell anemia.

Conflict of Interests: None

Limitations of study

Limited sample size.

Area based research.

References

1. Nathan and Oski's hematology of infancy and childhood. Vol 1, Page 803-808. (6th Edition).
2. Lee MT, Piomelli S, Granger S, Miller ST, Harkness S, Brambilla DJ, Adams RJ. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. *Blood*. 2006 Aug 1;108(3):847-52.

3. Swaiman KF, Ashwal S, Ferriero DM. Pediatric neurology: principles & practice, Vol 2, (5th Edition) Page 1410-1411. Elsevier Health Sciences; 2006.
 4. Singhal RP, Bansal H, Jain M, Lakhar B, Jain S. Sickle Children Vs Normal Children: A Transcranial and Extracranial Doppler Study.
 5. Brousse V, Kossorotoff M, Montalembert M. How I manage cerebral vasculopathy in children with sickle cell disease. *British journal of haematology*. 2015 Sep 1;170(5):615-25.
 6. Neish AS, Blews DE, Simms CA, Merritt RK, Spinks AJ. Screening for stroke in sickle cell anemia: comparison of transcranial Doppler imaging and nonimaging US techniques. *Radiology*. 2002 Mar;222(3):709-14.
 7. Pawlak MA, Krejza J, Rudzinski W, Kwiatkowski JL, Ichord R, Jawad AF, Tomaszewski M, Melhem ER. Sickle cell disease: ratio of blood flow velocity of intracranial to extracranial cerebral arteries – initial experience. *Radiology*. 2009 May;251(2):525-34.
 8. Munube D, Katabira E, Ndeezee G, Joloba M, Lhatoo S, Sajatovic M, Tumwine JK. Prevalence of stroke in children admitted with sickle cell anaemia to Mulago Hospital. *BMC neurology*. 2016 Sep 17;16(1):175.
 9. Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. *The Cochrane Library*. 2017 Jan 1.
 10. Green NS, Barral S. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. *Pediatric research*. 2013 Nov 19;75(1-2):196-204.
 11. Kratovil T, Bulas D, Driscoll MC, Speller Brown B, McCarter R, Minniti CP. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. *Pediatric blood & cancer*. 2006 Dec 1;47(7):894-900.
 12. Rankine-Mullings AE, Little CR, Reid ME, Soares DP, Taylor-Bryan C, Knight-Madden JM, Stuber SE, Badaloo AV, Aldred K, Wisdom-Phipps ME, Latham T. EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia. *JMIR research protocols*. 2016 Jul;5(3).
 13. Jeste ND, Sánchez LM, Urcuyo GS, Bergés ME, Luden JP, Stuber SE, Latham TS, Mena R, Nieves RM, Ware RE. Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia. *JMIR Research Protocols*. 2017;6(6):e107.
 14. Ghafari DL, Chaturvedi S, Rodeghier M, Stimpson SJ, McClain B, Byrd J, DeBaun MR. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia. *Pediatric blood & cancer*. 2017 Jul 1;64(7).
-